ArticleFrontiers in cellular neuroscience2026
Cerebrospinal fluid lipid profiles as exploratory biomarkers for pediatric meningitis: a proof-of-concept case series.
Article in Frontiers in cellular neuroscience, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objectives: To investigate the cerebrospinal fluid (CSF) lipid metabolite profiles of pediatric patients with purulent meningitis (PM) or viral meningitis (VM) and to explore their differential diagnostic potential. Methods: In this proof-of-concept case series, 13 CSF samples from 10 pediatric patients were analyzed by lipidomics, distributed across four sample-level analytical groups: acute-phase PM (PM_A, Results: Compared with the N group, the PM_A group displayed exploratory lipid alterations with 30 increased and 45 decreased metabolites, predominantly involving sphingolipid (SPH), dihexosylceramide (Hex2Cer), monohexosylceramide (Hex1Cer), lysophosphatidylcholine (LPC), and acylcarnitine (AcCa) species. Elevated Hex2Cer combined with reduced SPH represented a distinctive exploratory PM_A pattern. Receiver operating characteristic (ROC) analysis identified LPC(20:3) and Hex2Cer(d42:3) as exploratory candidate features for distinguishing PM_A from N (apparent AUC = 0.833 for each marker; leave-one-out jackknife AUC range 0.750-1.000, mean 0.833). Multi-feature composite AUCs were not reported because, at Conclusion: Cerebrospinal fluid lipidomics revealed disease-stage-specific alterations in pediatric PM and VM. These findings should be regarded as hypothesis-generating in this small proof-of-concept cohort and require validation in larger pediatric studies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.